

Republic of the Philippines Department of Health FOOD AND DRUG ADMINISTRATION



15 March 2013

DOH-FDA Advisory 2013- 004-

SUBJECT PUBLIC HEALTH ADVISORY ON ARO BARO CHURO ORGANIC TEA, ARO GUYABANO TEA AND ARO BARO CHURO GUYABANO CAPSULES

The FDA warns the public to refrain from buying unregistered health products, and food supplements and herbal products with label claims as anti-cancer or as cure against cancer.

The FDA has verified reports from concerned parties that the following food supplement products: *Aro Baro Churo Organic Tea, Aro Guyabano Tea* and *Aro Baro Churo Guyabano Capsule* are being sold and distributed nationwide with label claims that are not approved by the Food and Drug Administration. The said products have been fraudulently and deceptively labeled as 10,000 times stronger than chemotherapy and that they contain Adriamycin that can kill cancer cells. Upon verification, the FDA records showed that these products are neither registered as herbal drugs nor as food supplements.



The public is, hereby, warned not to buy any food supplements or herbal drug preparations that are not approved by the FDA or any products that claim to cure, treat or mitigate any form of cancer diseases. These products are not only ineffective and expensive, but they may cause adverse reactions and events, some of which may be life-threatening.

All FDA Regional Field Offices are ordered to continuously conduct monitoring and spot checking for these types of products in the market, and for all FDA inspectors nationwide to coordinate with the local government units (LGU) in ensuring that these unapproved products do

not proliferate in the market. All unregistered products found in all outlets or in the possession of vendors shall be seized immediately and reports shall be submitted to the FDA Legal Support Service Center for appropriate actions.

The manufacture, importation, selling or offering for sale of unregistered health product is a violation of Republic Act No. 3720, as amended by Republic Act No. 9711.

KENNETH Y. HARTIGAN-GO, MD
Acting Director IV